nach oben

Erschienen in:

15.09.2020 | Original article

Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis

verfasst von: Mengmeng Tang, Xue Zhang, Xueqian Li, Lei Lei, Hejia Zhang, Chen Ling, Jie Ni, Jicheng Lv, Xiaorong Liu, Xiangmei Chen

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

IgA nephropathy (IgAN) and IgA vasculitis with nephritis (IgAV-N) are related diseases. Galactose-deficient IgA1 (Gd-IgA1) plays an important role in the pathology of IgAV-N and IgAN, so we aim to compare the serum levels of Gd-IgA1 in Chinese pediatric patients with IgAN, IgAV-N, and IgAV.

Methods

We retrospectively enrolled 52 patients with IgAN, 57 patients with IgAV-N, 26 patients with IgAV, and 40 healthy children. The serum levels of Gd-IgA1 were measured at the time of biopsy using a lectin-based ELISA method.

Results

Gd-IgA1 levels in IgAV-N patients and IgAN patients were higher than in healthy controls (303.94 ± 39.37 U/ml, 314.91 ± 47.79 U/ml vs. 273.57 ± 48.29 U/ml, P < 0.001), and Gd-IgA1 levels in IgAV-N patients were higher than in IgAV patients (303.94 ± 39/ml vs. 286. 21 ± 38.81 U/ml, P = 0.059), but the latter result is not statistically significant. The Gd-IgA1 levels in IgAV patients were comparable with those in healthy controls (286.21 ± 38.81 U/ml vs. 273.57 ± 48.29 U/ml, P = 0.267). Among the four groups, we did not observe significant correlations of Gd-IgA1 levels with eGFR, proteinuria, or the MEST-C score.

Conclusion

Serum Gd-IgA1 maybe involved in the pathogenesis of the IgAV-N and IgAN. However, we found no statistically significant correlation between Gd-IgA1 levels and clinical and pathological features.

Chen JY, Mao JH. Henoch-Schonlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015;11(1):29–34. https://doi.org/10.1007/s12519-014-0534-5.CrossRefPubMed

Pohl M. Henoch-Schonlein purpura nephritis. PediatrNephrol. 2015;30(2):245–52. https://doi.org/10.1007/s00467-014-2815-6.CrossRef

Davin JC, Coppo R. Henoch-Schonlein purpura nephritis in children. Nat Rev Nephrol. 2014;10(10):563–73. https://doi.org/10.1038/nrneph.2014.126.CrossRefPubMed

Magistroni R, D'Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974–89. https://doi.org/10.1038/ki.2015.252.CrossRefPubMedPubMedCentral

Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. PediatrNephrol. 2018;33(5):763–77. https://doi.org/10.1007/s00467-017-3699-z.CrossRef

Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis? Kidney Int. 2001;59(3):823–34. https://doi.org/10.1046/j.1523-1755.2001.059003823.x.CrossRefPubMed

Li YT, Lv JC, Li GT, Jiang L, Song YH, Zhang H. Comparative analysis of clinicopathological findings and outcome of Henoch-Schonlein nephritis and IgA nephropathy in adults. J Peking Univ Health Sci. 2007;39(5):458–61.

Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700–5. https://doi.org/10.1016/j.kint.2017.10.019.CrossRefPubMed

Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney Int. 2011;80(1):79–877. https://doi.org/10.1038/ki.2011.16.CrossRefPubMedPubMedCentral

10.

Bagchi S, Lingaiah R, Mani K, Barwad A, Singh G, Balooni V, et al. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study. PLoS ONE. 2019;14(3):e0214256. https://doi.org/10.1371/journal.pone.0214256.CrossRefPubMedPubMedCentral

11.

Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82(7):790–6. https://doi.org/10.1038/ki.2012.197.CrossRefPubMedPubMedCentral

12.

Zhang X, Xie X, Shi S, Liu L, Lv J, Zhang H. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. Nephrol Dial Transpl. 2019. https://doi.org/10.1093/ndt/gfz151.CrossRef

13.

Kang ZJ, Liu B, Li ZH, Duan CR, Wu TH, Xun M, et al. Value of galactose-deficient IgA1 in the early diagnosis of Henoch-Schonlein purpura nephritis in children. Chin J Contemp Pediatr. 2019;21(2):172–5.

14.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. https://doi.org/10.1002/art.37715.CrossRefPubMed

15.

Neufeld M, Molyneux K, Pappelbaum KI, Mayer-Hain S, von Hodenberg C, Ehrchen J, et al. Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis. J Am Acad Dermatol. 2019;81(5):1078–85. https://doi.org/10.1016/j.jaad.2019.03.029.CrossRefPubMed

16.

Mizerska-Wasiak M, Gajewski L, Cichon-Kawa K, Maldyk J, Dziedzic-Jankowska K, Leszczynska B, et al. Serum GDIgA1 levels in children with IgA nephropathy and Henoch-Schonlein nephritis. Central-Eur J Immunol. 2018;43(2):162–7. https://doi.org/10.5114/ceji.2018.77386.CrossRef

17.

Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, et al. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. PLoS ONE. 2018;13(11):e0206865. https://doi.org/10.1371/journal.pone.0206865.CrossRefPubMedPubMedCentral

18.

Lau KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schonlein purpura. PediatrNephrol. 2007;22(12):2067–72. https://doi.org/10.1007/s00467-007-0623-y.CrossRef

19.

Vidal-Petiot E, Flamant M. Measurement and estimation of glomerular filtration rate. NephrolTher. 2017;13(7):560–8. https://doi.org/10.1016/j.nephro.2017.10.001.CrossRef

20.

Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–36. https://doi.org/10.1038/ki.2014.63.CrossRefPubMedPubMedCentral

21.

Markowitz G. Glomerular disease: updated Oxford classification of IgA nephropathy: a new MEST-C score. Nat Rev Nephrol. 2017;13(7):385–6. https://doi.org/10.1038/nrneph.2017.67.CrossRefPubMed

22.

Xu K, Zhang L, Ding J, Wang S, Su B, Xiao H, et al. Value of the Oxford classification of IgA nephropathy in children with Henoch-Schonlein purpura nephritis. J Nephrol. 2018;31(2):279–86. https://doi.org/10.1007/s40620-017-0457-z.CrossRefPubMed

23.

Allen AC, Willis FR, Beattie TJ, Feehally J. Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transpl. 1998;13(4):930–4. https://doi.org/10.1093/ndt/13.4.930.CrossRef

24.

Shima Y, Nakanishi K, Hama T, Sato M, Mukaiyama H, Togawa H, et al. Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy. PediatrNephrol. 2015;30(2):293–9. https://doi.org/10.1007/s00467-014-2862-z.CrossRef

25.

Jiang XY, Mo Y, Sun LZ, Yue ZH, Chen SM, Wu W. Efficacy of methylprednisolone, cyclophosphamide in pediatric IgA nephropathy assessed by renal biopsy. Clin Nephrol. 2009;71(6):625–31. https://doi.org/10.5414/cnp71625.CrossRefPubMed

26.

Roccatello D, Rossi D, Marletto F, Naretto C, Sciascia S, Baldovino S, et al. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. J Nephrol. 2012;25(2):198–203. https://doi.org/10.5301/JN.2011.8452.CrossRefPubMed

27.

Nguyen C, Konig K, Tam FWK, Hopfer H, Molyneux K, Binet FI, et al. Higher serum galactose-deficient immunoglobulin A1 concentration is associated with stronger mesangial cellular inflammatory response and more severe histologic findings in immunoglobulin A nephropathy. Clin Kidney J. 2019;12(2):232–8. https://doi.org/10.1093/ckj/sfy068.CrossRefPubMed

28.

Yanagihara T, Brown R, Hall S, Moldoveanu Z, Goepfert A, Tomana M, et al. In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. Results Immunol. 2012;2:166–72. https://doi.org/10.1016/j.rinim.2012.08.002.CrossRefPubMedPubMedCentral

29.

Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transpl. 2015;30(8):1315–21. https://doi.org/10.1093/ndt/gfv221.CrossRef

Titel: Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis
verfasst von: Mengmeng Tang
Xue Zhang
Xueqian Li
Lei Lei
Hejia Zhang
Chen Ling
Jie Ni
Jicheng Lv
Xiaorong Liu
Xiangmei Chen
Publikationsdatum: 15.09.2020
Verlag: Springer Singapore
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 1/2021
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-020-01968-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis

Abstract

Objective

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Association between urinary salt excretion and albuminuria in Japanese patients with chronic kidney disease: the Fukuoka kidney disease registry study

Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome

Zebra bodies without Fabry disease or hydroxychloroquine

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan

Serum uromodulin is a novel renal function marker in the Japanese population

Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin